# Liothyronine Positional Statement

For new patients liothyronine in combination with levothyroxine (L-T4) is **BLACK** to ensure initiation is in exceptional patients only.

Liothyronine (L-T3) for monotherapy, resistant depression and doses exceeding 60mcg per day is **RED**.

For existing patients*, following review of benefit by an NHS Endocrinologist Specialist, liothyronine in combination with levothyroxine is **AMBER** (see shared care).

---

**This commissioning statement has been produced and endorsed by JAPC in response to an evidence review on the use of liothyronine, its cost effectiveness and affordability. This position statement is supported by local primary care clinicians and written in consultation with endocrinologists from provider organisations across Derbyshire.**

Liothyronine is the JAPC treatment of choice for hypothyroidism. It is cost-effective, suitable for once daily dosing, and provides stable and physiological quantities of a thyroid hormone for patients requiring replacement.

All new patients requiring thyroid replacement will be initiated on **levothyroxine**.

**For existing patients** on liothyronine - following specialist review to determine ongoing need, patients currently receiving liothyronine in combination with levothyroxine (L-T3 & L-T4) for **hypothyroidism** may continue treatment under a Derbyshire Shared Care Agreement - **AMBER** classification. Periodic reviews of ongoing need for liothyronine and potential dose reductions will be undertaken.

**For new patients*** requiring liothyronine - liothyronine in combination with levothyroxine has been classified as **BLACK**.

Liothyronine is in the **BLACK** section of the traffic light drug list in Derbyshire and cannot be initiated in new patients. If there is an exceptional clinical need, such as difficulty in tolerating or absorbing levothyroxine, then a request to prescribe must be made via the IFR process and the request should be made by an NHS endocrinologist. Quality of life and other symptoms relating to patients lack of well-being on levothyroxine monotherapy will not pass the test of exceptionality and these patients should not be referred with the expectation that an IFR will be submitted. They can however still be referred to an endocrinologist for further evaluation of their symptoms to exclude other underlying medical conditions as well as optimisation of levothyroxine therapy.

**Liothyronine** when used as monotherapy, for resistant depression and in doses that exceed 60mcg per day for any indication has been classified **RED**.

Desiccated thyroid products are classified as **BLACK** e.g. Armour thyroid/ERFA. These are unlicensed products in the UK, derived from pig thyroid, and contain an excessive amount of L-T3 in relation to LT-4.

Patients who have been seen privately should be referred back to the private service if practicable, for continued private prescription of liothyronine or desiccated thyroid products (e.g. Armour thyroid/ERFA) or recommendation of an alternative treatment. Patients who wish to opt back into the NHS within Derby and Derbyshire CCG commissioning geography will be treated as a new patient and assessed in the same patient pathway as a NHS patient.

Exceptional acute use of liothyronine is permitted in oncology treatment and for diagnostic purposes in line with the British Thyroid cancer guidelines. (Classified as RED)
*commenced on treatment prior to the publication of this statement (October 2019)

**The symptoms of an underactive thyroid are not specific to the thyroid and may be due to many other conditions. If the TSH is within the reference range and dose adjustment has not helped, then the doctor should look for other causes of these symptoms. The list of possible alternative conditions is long but includes pernicious anaemia, coeliac disease, vitamin D deficiency, sleep apnoea, poor lifestyle and lack of sleep, depression, fibromyalgia, chronic fatigue syndrome and side-effects of medications.

***considered for treatment after publication of this statement (October 2019)

Specialist review and managing existing patients being treated with liothyronine
The overall aim is to avoid over or under replacement with thyroid hormones. The suggested process is a gradual reduction of liothyronine while slowly introducing or increasing levothyroxine. This may help patients tolerate the change. 20-25mcg of liothyronine Sodium is equivalent to approximately 100mcg of levothyroxine Sodium.

Check TSH level before changing the patient's medications (every 4-6 weeks).

- If TSH is in the normal range introduce/increase levothyroxine by 25-50 mcg for every 10mcg of liothyronine reduction. Continue gradual reduction of liothyronine and increase of levothyroxine until patient is biochemically euthyroid and off Liothyronine.
- If starting TSH is <0.3mIU/L, reduce Liothyronine first by 10mcg every 4-6 weeks until TSH is in the normal range and then follow above advice.
- If TSH is >5.5mIU/L introduce/increase levothyroxine by 25mcg until TSH is in the normal range then follow above advice

Rationale

Cost effectiveness and affordability.
Levothyroxine (L-T4) is a pro-drug and is converted to liothyronine (L-T3) in the body. The price of liothyronine has increased significantly (in excess of 1000% since 2009) to the extent that JAPC now considers that on balance the £500k spend over 12 months for liothyronine, is no longer cost effective or affordable.

Desiccated thyroid compounds like Armour thyroid compared to levothyroxine are expensive for the NHS (a month of levothyroxine 100mcg costs less than £2.00, compared to around £40.00 for a month of natural desiccated thyroid of 120mg), with no obvious benefit.

Evidence and safety.
There is currently insufficient evidence of clinical and cost effectiveness to support the routine use of liothyronine (either alone or in combination) for the treatment of hypothyroidism.

1. Liothyronine is considered an experimental approach by the European Thyroid Association in compliant levothyroxine-treated hypothyroid patients who have persistent complaints despite serum TSH values within the reference range. There is currently insufficient evidence to support the routine use of liothyronine outside a formal clinical trial.

2. The combination of levothyroxine and liothyronine, in both non-psychological and physiological proportions, has not consistently shown to be more beneficial than levothyroxine alone with respect to cognitive function, social functioning and wellbeing. The variation in hormonal content and large amounts of liothyronine may lead to increased serum concentrations of liothyronine and subsequent thyrotoxic symptoms, such as palpitations and tremor.
3. Although some people report feeling better on liothyronine and levothyroxine, in “blinded” clinical trials, patients have not been able to tell the difference, except perhaps at high dose. It is harder to select, monitor and adjust the dose of liothyronine containing preparations than levothyroxine, and it is likely therefore that using liothyronine and levothyroxine will increase the risk of stroke and osteoporosis from slight over treatment over many years.

4. Liothyronine has a much shorter half-life and steady-state levels cannot be maintained with once daily dosing.

5. Unlicensed products e.g. Armour Thyroid, ERFA are not subject to the same assurances of quality, safety and efficacy as licensed medicines and should not be prescribed where a licensed product like levothyroxine is available.

Further resources
Switching from liothyronine (LT-3) to levothyroxine (LT-4)
- Frequently Asked Questions for GP’s
- Frequently Asked Questions for patients
- Information for Endocrinologists

Reference
3. Presqipp bulletin 121 Switching liothyronine (L-T3) to levothyroxine (L-T4) in the management of primary hypothyroidism. December 2015